Header Logo

Connection

Alan Schneyer to Humans

This is a "connection" page, showing publications Alan Schneyer has written about Humans.
Connection Strength

0.399
  1. Brown ML, Schneyer A. A Decade Later: Revisiting the TGF? Family's Role in Diabetes. Trends Endocrinol Metab. 2021 01; 32(1):36-47.
    View in: PubMed
    Score: 0.028
  2. Brown ML, Ungerleider N, Bonomi L, Andrzejewski D, Burnside A, Schneyer A. Effects of activin A on survival, function and gene expression of pancreatic islets from non-diabetic and diabetic human donors. Islets. 2014; 6(5-6):e1017226.
    View in: PubMed
    Score: 0.017
  3. Ungerleider NA, Bonomi LM, Brown ML, Schneyer AL. Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice. Endocrinology. 2013 Jun; 154(6):2025-33.
    View in: PubMed
    Score: 0.016
  4. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol. 2009 Jul; 202(1):1-12.
    View in: PubMed
    Score: 0.012
  5. Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology. 2008 Sep; 149(9):4589-95.
    View in: PubMed
    Score: 0.012
  6. Lambert-Messerlian G, Eklund E, Pinar H, Tantravahi U, Schneyer AL. Activin subunit and receptor expression in normal and cleft human fetal palate tissues. Pediatr Dev Pathol. 2007 Nov-Dec; 10(6):436-45.
    View in: PubMed
    Score: 0.011
  7. Mukherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen ED, Bloch KD, Thomas MK, Schneyer AL. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci U S A. 2007 Jan 23; 104(4):1348-53.
    View in: PubMed
    Score: 0.011
  8. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006 Jul; 147(7):3586-97.
    View in: PubMed
    Score: 0.010
  9. Saito S, Sidis Y, Mukherjee A, Xia Y, Schneyer A. Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3. Endocrinology. 2005 Dec; 146(12):5052-62.
    View in: PubMed
    Score: 0.010
  10. Welt CK, Taylor AE, Fox J, Messerlian GM, Adams JM, Schneyer AL. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J Clin Endocrinol Metab. 2005 Oct; 90(10):5582-7.
    View in: PubMed
    Score: 0.009
  11. Xia Y, Sidis Y, Mukherjee A, Samad TA, Brenner G, Woolf CJ, Lin HY, Schneyer A. Localization and action of Dragon (repulsive guidance molecule b), a novel bone morphogenetic protein coreceptor, throughout the reproductive axis. Endocrinology. 2005 Aug; 146(8):3614-21.
    View in: PubMed
    Score: 0.009
  12. del Re E, Sidis Y, Fabrizio DA, Lin HY, Schneyer A. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J Biol Chem. 2004 Dec 17; 279(51):53126-35.
    View in: PubMed
    Score: 0.009
  13. Schneyer AL, Wang Q, Sidis Y, Sluss PM. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab. 2004 Oct; 89(10):5067-75.
    View in: PubMed
    Score: 0.009
  14. Schneyer A, Schoen A, Quigg A, Sidis Y. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology. 2003 May; 144(5):1671-4.
    View in: PubMed
    Score: 0.008
  15. Seifer DB, Lambert-Messerlian G, Schneyer AL. Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women. Fertil Steril. 2003 Feb; 79(2):451-2.
    View in: PubMed
    Score: 0.008
  16. Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood). 2002 Oct; 227(9):724-52.
    View in: PubMed
    Score: 0.008
  17. Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology. 2002 May; 143(5):1613-24.
    View in: PubMed
    Score: 0.008
  18. Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, Fox J, Taylor A, Schneyer A. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. J Clin Endocrinol Metab. 2001 Sep; 86(9):4206-15.
    View in: PubMed
    Score: 0.007
  19. Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology. 2001 Aug; 142(8):3426-34.
    View in: PubMed
    Score: 0.007
  20. Schneyer A, Tortoriello D, Sidis Y, Keutmann H, Matsuzaki T, Holmes W. Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol Cell Endocrinol. 2001 Jun 30; 180(1-2):33-8.
    View in: PubMed
    Score: 0.007
  21. Welt CK, Schneyer AL. Differential regulation of inhibin B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles. J Clin Endocrinol Metab. 2001 Jan; 86(1):330-6.
    View in: PubMed
    Score: 0.007
  22. Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab. 2000 Sep; 85(9):3319-30.
    View in: PubMed
    Score: 0.007
  23. Fujiwara T, Lambert-Messerlian G, Sidis Y, Leykin L, Isaacson K, Toth T, Schneyer A. Analysis of follicular fluid hormone concentrations and granulosa cell mRNA levels for the inhibin-activin-follistatin system: relation to oocyte and embryo characteristics. Fertil Steril. 2000 Aug; 74(2):348-55.
    View in: PubMed
    Score: 0.007
  24. Delbaere A, Sidis Y, Schneyer AL. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin. Endocrinology. 1999 Jun; 140(6):2463-70.
    View in: PubMed
    Score: 0.006
  25. Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T, Schneyer AL. Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Biol Reprod. 1998 Oct; 59(4):807-12.
    View in: PubMed
    Score: 0.006
  26. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab. 1997 Nov; 82(11):3720-7.
    View in: PubMed
    Score: 0.006
  27. Lambert-Messerlian G, Taylor A, Leykin L, Isaacson K, Toth T, Chang Y, Schneyer A. Characterization of intrafollicular steroid hormones, inhibin, and follistatin in women with and without polycystic ovarian syndrome following gonadotropin hyperstimulation. Biol Reprod. 1997 Nov; 57(5):1211-6.
    View in: PubMed
    Score: 0.006
  28. Lambert-Messerlian GM, Steinhoff M, Zheng W, Canick JA, Gajewski WH, Seifer DB, Schneyer AL. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol. 1997 Jun; 65(3):512-6.
    View in: PubMed
    Score: 0.005
  29. Schneyer AL. Measurement of activin in physiological fluids. Eur J Endocrinol. 1996 Apr; 134(4):401-2.
    View in: PubMed
    Score: 0.005
  30. Seifer DB, Lambert-Messerlian GM, Canick JA, Frishman GN, Schneyer AL. Serum inhibin levels are lower in ectopic than intrauterine spontaneously conceived pregnancies. Fertil Steril. 1996 Mar; 65(3):667-9.
    View in: PubMed
    Score: 0.005
  31. Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology. 1996 Feb; 137(2):486-94.
    View in: PubMed
    Score: 0.005
  32. Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. J Clin Endocrinol Metab. 1996 Feb; 81(2):736-9.
    View in: PubMed
    Score: 0.005
  33. Canali S, Core AB, Zumbrennen-Bullough KB, Merkulova M, Wang CY, Schneyer AL, Pietrangelo A, Babitt JL. Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice. Endocrinology. 2016 Mar; 157(3):1146-62.
    View in: PubMed
    Score: 0.005
  34. Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley WF. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology. 1996 Jan; 137(1):240-7.
    View in: PubMed
    Score: 0.005
  35. Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. J Med Screen. 1996; 3(2):58-62.
    View in: PubMed
    Score: 0.005
  36. Lambert-Messerlian GM, Crowley WF, Schneyer AL. Extragonadal alpha-inhibin precursor proteins circulate in human male serum. J Clin Endocrinol Metab. 1995 Oct; 80(10):3043-9.
    View in: PubMed
    Score: 0.005
  37. Nam J, Perera P, Gordon R, Jeong YH, Blazek AD, Kim DG, Tee BC, Sun Z, Eubank TD, Zhao Y, Lablebecioglu B, Liu S, Litsky A, Weisleder NL, Lee BS, Butterfield T, Schneyer AL, Agarwal S. Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening. Bone. 2015 Sep; 78:62-70.
    View in: PubMed
    Score: 0.005
  38. Schneyer AL, Rzucidlo DA, Sluss PM, Crowley WF. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology. 1994 Aug; 135(2):667-74.
    View in: PubMed
    Score: 0.004
  39. Lambert-Messerlian GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WF, Schneyer AL. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 1994 Jul; 79(1):45-50.
    View in: PubMed
    Score: 0.004
  40. Lambert-Messerlian GM, Isaacson K, Crowley WF, Sluss P, Schneyer AL. Human follicular fluid contains pro- and C-terminal immunoreactive alpha-inhibin precursor proteins. J Clin Endocrinol Metab. 1994 Feb; 78(2):433-9.
    View in: PubMed
    Score: 0.004
  41. Sluss PM, Gentile DP, Ewing JF, Schoen SR, Cockett AT, Martin KA, Schneyer AL. Multiple molecular weight forms of immunoreactive alpha-inhibin in human seminal plasma. J Clin Endocrinol Metab. 1993 Feb; 76(2):476-83.
    View in: PubMed
    Score: 0.004
  42. Sluss PM, Schneyer AL. Low molecular weight follicle-stimulating hormone receptor binding inhibitor in sera from premature ovarian failure patients. J Clin Endocrinol Metab. 1992 Jun; 74(6):1242-6.
    View in: PubMed
    Score: 0.004
  43. Schneyer AL, O'Neil DA, Crowley WF. Activin-binding proteins in human serum and follicular fluid. J Clin Endocrinol Metab. 1992 Jun; 74(6):1320-4.
    View in: PubMed
    Score: 0.004
  44. Schneyer AL, Sluss PM, Whitcomb RW, Martin KA, Sprengel R, Crowley WF. Precursors of alpha-inhibin modulate follicle-stimulating hormone receptor binding and biological activity. Endocrinology. 1991 Oct; 129(4):1987-99.
    View in: PubMed
    Score: 0.004
  45. Dunphy KA, Schneyer AL, Hagen MJ, Jerry DJ. The role of activin in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia. 2011 Jun; 16(2):117-26.
    View in: PubMed
    Score: 0.004
  46. Schneyer AL, Sluss PM, Whitcomb RW, Hall JE, Crowley WF, Freeman RG. Development of a radioligand receptor assay for measuring follitropin in serum: application to premature ovarian failure. Clin Chem. 1991 Apr; 37(4):508-14.
    View in: PubMed
    Score: 0.004
  47. Whitcomb RW, Schneyer AL. Development and validation of a radioligand receptor assay for measurement of luteinizing hormone in human serum. J Clin Endocrinol Metab. 1990 Sep; 71(3):591-5.
    View in: PubMed
    Score: 0.003
  48. Schneyer AL, Mason AJ, Burton LE, Ziegner JR, Crowley WF. Immunoreactive inhibin alpha-subunit in human serum: implications for radioimmunoassay. J Clin Endocrinol Metab. 1990 Apr; 70(4):1208-12.
    View in: PubMed
    Score: 0.003
  49. Thadhani R, Powe CE, Tjoa ML, Khankin E, Ye J, Ecker J, Schneyer A, Karumanchi SA. First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus. Diabetes Care. 2010 Mar; 33(3):664-9.
    View in: PubMed
    Score: 0.003
  50. Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem. 2008 Nov 21; 283(47):32831-8.
    View in: PubMed
    Score: 0.003
  51. Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL, Lin HY. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem. 2007 Jun 22; 282(25):18129-18140.
    View in: PubMed
    Score: 0.003
  52. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006 May; 38(5):531-9.
    View in: PubMed
    Score: 0.002
  53. Schneyer A, Castro A, Odell D. Radioimmunoassay of serum follicle-stimulating hormone and luteinizing hormone in the bottlenosed dolphin. Biol Reprod. 1985 Nov; 33(4):844-53.
    View in: PubMed
    Score: 0.002
  54. Babitt JL, Zhang Y, Samad TA, Xia Y, Tang J, Campagna JA, Schneyer AL, Woolf CJ, Lin HY. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem. 2005 Aug 19; 280(33):29820-7.
    View in: PubMed
    Score: 0.002
  55. Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, Fabrizio DA, Schneyer AL, Lin HY, Brivanlou AH, Attisano L, Woolf CJ. DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem. 2005 Apr 08; 280(14):14122-9.
    View in: PubMed
    Score: 0.002
  56. Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer A, Canick JA. Inhibins and activins in human fetal abnormalities. Mol Cell Endocrinol. 2004 Oct 15; 225(1-2):101-8.
    View in: PubMed
    Score: 0.002
  57. Sidis Y, Schneyer AL, Keutmann HT. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology. 2005 Jan; 146(1):130-6.
    View in: PubMed
    Score: 0.002
  58. del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem. 2004 May 21; 279(21):22765-72.
    View in: PubMed
    Score: 0.002
  59. Welt CK, Schneyer AL, Heist K, Mantzoros CS. Leptin and soluble leptin receptor in follicular fluid. J Assist Reprod Genet. 2003 Dec; 20(12):495-501.
    View in: PubMed
    Score: 0.002
  60. Keutmann HT, Schneyer AL, Sidis Y. The role of follistatin domains in follistatin biological action. Mol Endocrinol. 2004 Jan; 18(1):228-40.
    View in: PubMed
    Score: 0.002
  61. Di Simone N, Schneyer AL, Caliandro D, Castellani R, Caruso A. Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol. 2002 Jun 28; 192(1-2):187-95.
    View in: PubMed
    Score: 0.002
  62. Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT. Follistatin: essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem. 2001 May 25; 276(21):17718-26.
    View in: PubMed
    Score: 0.002
  63. Urbanek M, Wu X, Vickery KR, Kao LC, Christenson LK, Schneyer A, Legro RS, Driscoll DA, Strauss JF, Dunaif A, Spielman RS. Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000 Dec; 85(12):4455-61.
    View in: PubMed
    Score: 0.002
  64. Wang Q, Keutmann HT, Schneyer AL, Sluss PM. Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins. Endocrinology. 2000 Sep; 141(9):3183-93.
    View in: PubMed
    Score: 0.002
  65. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 1998 Apr; 69(1):23-31.
    View in: PubMed
    Score: 0.001
  66. McConnell DS, Wang Q, Sluss PM, Bolf N, Khoury RH, Schneyer AL, Midgley AR, Reame NE, Crowley WF, Padmanabhan V. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab. 1998 Mar; 83(3):851-8.
    View in: PubMed
    Score: 0.001
  67. Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF, Sluss PM. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology. 1996 Dec; 137(12):5476-83.
    View in: PubMed
    Score: 0.001
  68. Seifer DB, Freeman MR, Gardiner AC, Hill GA, Schneyer AL, Vanderhyden BC. Autologous granulosa cell coculture demonstrates zygote suppression of granulosa cell steroidogenesis. Fertil Steril. 1996 Sep; 66(3):425-9.
    View in: PubMed
    Score: 0.001
  69. Wang QF, Khoury RH, Smith PC, McConnell DS, Padmanahban V, Midgley AR, Schneyer AL, Crowley WF, Sluss PM. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab. 1996 Apr; 81(4):1434-41.
    View in: PubMed
    Score: 0.001
  70. Khoury RH, Wang QF, Crowley WF, Hall JE, Schneyer AL, Toth T, Midgley AR, Sluss PM. Serum follistatin levels in women: evidence against an endocrine function of ovarian follistatin. J Clin Endocrinol Metab. 1995 Apr; 80(4):1361-8.
    View in: PubMed
    Score: 0.001
  71. Santoro N, Schneyer AL, Ibrahim J, Schmidt CL. Gonadotropin and inhibin concentrations in early pregnancy in women with and without corpora lutea. Obstet Gynecol. 1992 Apr; 79(4):579-85.
    View in: PubMed
    Score: 0.001
  72. Landy H, Boepple PA, Mansfield MJ, Whitcomb RW, Schneyer AL, Crawford JD, Crigler JF, Crowley WF. Altered patterns of pituitary secretion and renal excretion of free alpha-subunit during gonadotropin-releasing hormone agonist-induced pituitary desensitization. J Clin Endocrinol Metab. 1991 Mar; 72(3):711-7.
    View in: PubMed
    Score: 0.001
  73. Sluss PM, Schneyer AL, Cockett AT, Cromie WJ. Identification of a potential FSH modulatory protein in human testis and seminal plasma. J Androl. 1989 Sep-Oct; 10(5):386-92.
    View in: PubMed
    Score: 0.001
  74. Whitcomb RW, Sangha JS, Schneyer AL, Crowley WF. Improved measurement of free alpha subunit of glycoprotein hormones by assay with use of a monoclonal antibody. Clin Chem. 1988 Oct; 34(10):2022-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.